MedTrace Logo

A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation

NCT03634683 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-06-30

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) represent approximately 70-85% of liver cancer, in which Hepatitis B virus (HBV) is the major etiologic agent accounting for at least 80% of HCC in Asian countries. Overall, transplantation remains the best option however, HCC recurrence rate is high among liver transplant patients.

While there are limited treatment measures for HBV-related HCC recurrences, the study hypothesized that LioCyx is capable of lysing target liver cells expressing the HBV cognate antigens and provide clinical benefit to patients with HBV-related HCC.

Conditions

  • Recurrent Hepatocellular Carcinoma

Interventions

BIOLOGICAL

LioCyx

Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR

Sponsors & Collaborators

  • Lion TCR Pte. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • China
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03634683 on ClinicalTrials.gov